Current investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing encouraging effects in addressing excess mass and related 2 diabetes. Initial data suggest a unique mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/